Reviews Adalimumab


No reviews yet.

Humira Drug Description
HUMIRA
(adalimumab) Injection, Solution for Subcutaneous Use

WARNINGS
SERIOUS INFECTIONS
Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
HUMIRA should be discontinued if a patient develops a serious infection or sepsis.
Reported infections include:

Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before HUMIRA use and during therapy. Treatment for latent infection should be initiated prior to HUMIRA use.
Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocys-tosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
Bacterial, viral and other infections due to opportunistic pathogens.

The risks and benefits of treatment with HUMIRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. [See WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which HUMIRA is a member

DRUG DESCRIPTION



What are the possible side effects of adalimumab (Humira, Humira Pen, Humira Pen Crohn's Disease Starter Package)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Serious and sometimes fatal infections may occur during treatment with adalimumab. Stop using adalimumab and call your doctor right away if you have signs of infection such as:

fever, sweating, chills, tired feeling;
feeling short of breath;
cough, sore...
Read All Potential Side Effects for Humira »




HUMIRA (adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). HUMIRA was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. Adalimumab is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.
HUMIRA is supplied as a sterile, preservative-free solution of adalimumab for subcutaneous administration. The drug product is supplied as either a single-use, prefilled pen (HUMIRA Pen) or as a single-dose, 1 mL prefilled glass syringe. Enclosed within the pen is a single-use, 1 mL prefilled glass syringe. The solution of HUMIRA is clear and colorless, with a pH of about 5.2. Each prefilled syringe delivers 0.8 mL (40 mg) of drug product. Each 0.8 mL of HUMIRA contains 40 mg adalimumab, 4.93 mg sodium chloride, 0.69 mg monobasic sodium phosphate dihydrate, 1.22 mg dibasic sodium phosphate dihydrate, 0.24 mg sodium citrate, 1.04 mg citric acid monohydrate, 9.6 mg mannitol, 0.8 mg polysorbate 80, and Water for Injection, USP. Sodium hydroxide added as necessary to adjust pH. Each pediatric prefilled syringe delivers 0.4 mL (20 mg) of drug product. Each 0.4 mL of HUMIRA contains 20 mg adalimumab, 2.47 mg sodium chloride, 0.34 mg monobasic sodium phosphate dihydrate, 0.61 mg dibasic sodium phosphate dihydrate, 0.12 mg sodium citrate, 0.52 mg citric acid monohydrate, 4.8 mg mannitol, 0.4 mg polysorbate 80, and Water for Injection, USP. Sodium hydroxide added as necessary to adjust pH.
Last reviewed on RxList: 8/27/2010




Humira Drug Description
HUMIRA
(adalimumab) Injection, Solution for Subcutaneous Use

WARNINGS
SERIOUS INFECTIONS
Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
HUMIRA should be discontinued if a patient develops a serious infection or sepsis.
Reported infections include:

Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before HUMIRA use and during therapy. Treatment for latent infection should be initiated prior to HUMIRA use.
Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocys-tosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
Bacterial, viral and other infections due to opportunistic pathogens.

The risks and benefits of treatment with HUMIRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. [See WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which HUMIRA is a member

DRUG DESCRIPTION



What are the possible side effects of adalimumab (Humira, Humira Pen, Humira Pen Crohn's Disease Starter Package)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Serious and sometimes fatal infections may occur during treatment with adalimumab. Stop using adalimumab and call your doctor right away if you have signs of infection such as:

fever, sweating, chills, tired feeling;
feeling short of breath;
cough, sore...
Read All Potential Side Effects for Humira »




HUMIRA (adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). HUMIRA was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. Adalimumab is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.
HUMIRA is supplied as a sterile, preservative-free solution of adalimumab for subcutaneous administration. The drug product is supplied as either a single-use, prefilled pen (HUMIRA Pen) or as a single-dose, 1 mL prefilled glass syringe. Enclosed within the pen is a single-use, 1 mL prefilled glass syringe. The solution of HUMIRA is clear and colorless, with a pH of about 5.2. Each prefilled syringe delivers 0.8 mL (40 mg) of drug product. Each 0.8 mL of HUMIRA contains 40 mg adalimumab, 4.93 mg sodium chloride, 0.69 mg monobasic sodium phosphate dihydrate, 1.22 mg dibasic sodium phosphate dihydrate, 0.24 mg sodium citrate, 1.04 mg citric acid monohydrate, 9.6 mg mannitol, 0.8 mg polysorbate 80, and Water for Injection, USP. Sodium hydroxide added as necessary to adjust pH. Each pediatric prefilled syringe delivers 0.4 mL (20 mg) of drug product. Each 0.4 mL of HUMIRA contains 20 mg adalimumab, 2.47 mg sodium chloride, 0.34 mg monobasic sodium phosphate dihydrate, 0.61 mg dibasic sodium phosphate dihydrate, 0.12 mg sodium citrate, 0.52 mg citric acid monohydrate, 4.8 mg mannitol, 0.4 mg polysorbate 80, and Water for Injection, USP. Sodium hydroxide added as necessary to adjust pH.
Last reviewed on RxList: 8/27/2010




Humira Drug Description
HUMIRA
(adalimumab) Injection, Solution for Subcutaneous Use

WARNINGS
SERIOUS INFECTIONS
Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
HUMIRA should be discontinued if a patient develops a serious infection or sepsis.
Reported infections include:

Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before HUMIRA use and during therapy. Treatment for latent infection should be initiated prior to HUMIRA use.
Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocys-tosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
Bacterial, viral and other infections due to opportunistic pathogens.

The risks and benefits of treatment with HUMIRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. [See WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which HUMIRA is a member

DRUG DESCRIPTION



What are the possible side effects of adalimumab (Humira, Humira Pen, Humira Pen Crohn's Disease Starter Package)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Serious and sometimes fatal infections may occur during treatment with adalimumab. Stop using adalimumab and call your doctor right away if you have signs of infection such as:

fever, sweating, chills, tired feeling;
feeling short of breath;
cough, sore...
Read All Potential Side Effects for Humira »




HUMIRA (adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). HUMIRA was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. Adalimumab is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.
HUMIRA is supplied as a sterile, preservative-free solution of adalimumab for subcutaneous administration. The drug product is supplied as either a single-use, prefilled pen (HUMIRA Pen) or as a single-dose, 1 mL prefilled glass syringe. Enclosed within the pen is a single-use, 1 mL prefilled glass syringe. The solution of HUMIRA is clear and colorless, with a pH of about 5.2. Each prefilled syringe delivers 0.8 mL (40 mg) of drug product. Each 0.8 mL of HUMIRA contains 40 mg adalimumab, 4.93 mg sodium chloride, 0.69 mg monobasic sodium phosphate dihydrate, 1.22 mg dibasic sodium phosphate dihydrate, 0.24 mg sodium citrate, 1.04 mg citric acid monohydrate, 9.6 mg mannitol, 0.8 mg polysorbate 80, and Water for Injection, USP. Sodium hydroxide added as necessary to adjust pH. Each pediatric prefilled syringe delivers 0.4 mL (20 mg) of drug product. Each 0.4 mL of HUMIRA contains 20 mg adalimumab, 2.47 mg sodium chloride, 0.34 mg monobasic sodium phosphate dihydrate, 0.61 mg dibasic sodium phosphate dihydrate, 0.12 mg sodium citrate, 0.52 mg citric acid monohydrate, 4.8 mg mannitol, 0.4 mg polysorbate 80, and Water for Injection, USP. Sodium hydroxide added as necessary to adjust pH.
Last reviewed on RxList: 8/27/2010




Humira Drug Description
HUMIRA
(adalimumab) Injection, Solution for Subcutaneous Use

WARNINGS
SERIOUS INFECTIONS
Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
HUMIRA should be discontinued if a patient develops a serious infection or sepsis.
Reported infections include:

Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before HUMIRA use and during therapy. Treatment for latent infection should be initiated prior to HUMIRA use.
Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocys-tosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
Bacterial, viral and other infections due to opportunistic pathogens.

The risks and benefits of treatment with HUMIRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. [See WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which HUMIRA is a member

DRUG DESCRIPTION



What are the possible side effects of adalimumab (Humira, Humira Pen, Humira Pen Crohn's Disease Starter Package)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Serious and sometimes fatal infections may occur during treatment with adalimumab. Stop using adalimumab and call your doctor right away if you have signs of infection such as:

fever, sweating, chills, tired feeling;
feeling short of breath;
cough, sore...
Read All Potential Side Effects for Humira »




HUMIRA (adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). HUMIRA was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. Adalimumab is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.
HUMIRA is supplied as a sterile, preservative-free solution of adalimumab for subcutaneous administration. The drug product is supplied as either a single-use, prefilled pen (HUMIRA Pen) or as a single-dose, 1 mL prefilled glass syringe. Enclosed within the pen is a single-use, 1 mL prefilled glass syringe. The solution of HUMIRA is clear and colorless, with a pH of about 5.2. Each prefilled syringe delivers 0.8 mL (40 mg) of drug product. Each 0.8 mL of HUMIRA contains 40 mg adalimumab, 4.93 mg sodium chloride, 0.69 mg monobasic sodium phosphate dihydrate, 1.22 mg dibasic sodium phosphate dihydrate, 0.24 mg sodium citrate, 1.04 mg citric acid monohydrate, 9.6 mg mannitol, 0.8 mg polysorbate 80, and Water for Injection, USP. Sodium hydroxide added as necessary to adjust pH. Each pediatric prefilled syringe delivers 0.4 mL (20 mg) of drug product. Each 0.4 mL of HUMIRA contains 20 mg adalimumab, 2.47 mg sodium chloride, 0.34 mg monobasic sodium phosphate dihydrate, 0.61 mg dibasic sodium phosphate dihydrate, 0.12 mg sodium citrate, 0.52 mg citric acid monohydrate, 4.8 mg mannitol, 0.4 mg polysorbate 80, and Water for Injection, USP. Sodium hydroxide added as necessary to adjust pH.
Last reviewed on RxList: 8/27/2010




Humira Drug Description
HUMIRA
(adalimumab) Injection, Solution for Subcutaneous Use

WARNINGS
SERIOUS INFECTIONS
Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
HUMIRA should be discontinued if a patient develops a serious infection or sepsis.
Reported infections include:

Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before HUMIRA use and during therapy. Treatment for latent infection should be initiated prior to HUMIRA use.
Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocys-tosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
Bacterial, viral and other infections due to opportunistic pathogens.

The risks and benefits of treatment with HUMIRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. [See WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which HUMIRA is a member

DRUG DESCRIPTION



What are the possible side effects of adalimumab (Humira, Humira Pen, Humira Pen Crohn's Disease Starter Package)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Serious and sometimes fatal infections may occur during treatment with adalimumab. Stop using adalimumab and call your doctor right away if you have signs of infection such as:

fever, sweating, chills, tired feeling;
feeling short of breath;
cough, sore...
Read All Potential Side Effects for Humira »




HUMIRA (adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). HUMIRA was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. Adalimumab is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.
HUMIRA is supplied as a sterile, preservative-free solution of adalimumab for subcutaneous administration. The drug product is supplied as either a single-use, prefilled pen (HUMIRA Pen) or as a single-dose, 1 mL prefilled glass syringe. Enclosed within the pen is a single-use, 1 mL prefilled glass syringe. The solution of HUMIRA is clear and colorless, with a pH of about 5.2. Each prefilled syringe delivers 0.8 mL (40 mg) of drug product. Each 0.8 mL of HUMIRA contains 40 mg adalimumab, 4.93 mg sodium chloride, 0.69 mg monobasic sodium phosphate dihydrate, 1.22 mg dibasic sodium phosphate dihydrate, 0.24 mg sodium citrate, 1.04 mg citric acid monohydrate, 9.6 mg mannitol, 0.8 mg polysorbate 80, and Water for Injection, USP. Sodium hydroxide added as necessary to adjust pH. Each pediatric prefilled syringe delivers 0.4 mL (20 mg) of drug product. Each 0.4 mL of HUMIRA contains 20 mg adalimumab, 2.47 mg sodium chloride, 0.34 mg monobasic sodium phosphate dihydrate, 0.61 mg dibasic sodium phosphate dihydrate, 0.12 mg sodium citrate, 0.52 mg citric acid monohydrate, 4.8 mg mannitol, 0.4 mg polysorbate 80, and Water for Injection, USP. Sodium hydroxide added as necessary to adjust pH.
Last reviewed on RxList: 8/27/2010





Other reviews about Adalimumab on wordpress

Abatacept-Orencia
  by hijadoo
U.S. BRAND NAMES — Orencia®PHARMACOLOGIC CATEGORY Antirheumatic, Disease ModifyingDOSING: ADULTS — Rheumatoid arthritis: I.V.: Dosing is according to body weight. Repeat dose at 2 weeks and 4 weeks […]


Adalimumab,Humira
  by hijadoo
U.S. BRAND NAMES — Humira®PHARMACOLOGIC CATEGORY Antirheumatic, Disease ModifyingMonoclonal AntibodyTumor Necrosis Factor (TNF) Blocking AgentDOSING: ADULTS Rheumatoid arthritis: SubQ: 40 mg every other week; may be administered with […]


One Reason for Schering's Stock Price Decline on Friday, June 13, 2008. . .
  by condor
I originally posted this elsewhere, but I thought I'd keep track of it -- for ease of future reference -- here: ". . . .Abbott [today] announced new […]


One Reason for Schering's Stock Price Decline on Friday, June 13, 2008. . .
  by condor
I originally posted this elsewhere, but I thought I'd keep track of it -- for ease of future reference -- here: ". . . .Abbott [today] announced new […]


Risk of serious fungal infections with Golimumab [Simponi]
  by thassodotcom
May 31, 2009 - In a safety information to rheumatological healthcare professionals, posted May 27, 2009, FDA and Centocor Ortho Biotech remind healthcare professionals of the risk of […]


Increased Risk for Lymphoma and Other Malignancies in Children and Adolescents Treated with Tumor Necrosis Factor - α (TNF - α) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi)
  by thassodotcom
August 9, 2009 -  On August 4, 2009, the US Food and Drug Administration (FDA) posted the following Safety Alert for Human Medicines (graphic added by the […]


Crohn’s disease - NICE recommends infliximab and adalimumab
  by rcplondon
In final draft guidance NICE has recommended infliximab and adalimumab as treatment options for people with severe, active Crohn’s disease whose condition has not responded to conventional therapy, […]


NICE draft guidance proposes treatment options for psoriatic arthritis
  by rcplondon
NICE has published draft guidance recommending etanercept (Enbrel, Wyeth Pharmaceuticals) and adalimumab (Humira, Abbott Laboratories) for the treatment of adults with active and progressive psoriatic arthritis when specific […]


Health Side Effects of Humira
  by Laura
For any anti-inflammatory disease, there are a variety of medicines available. One of the newer, more popular medicines on the market for anti-inflammatory diseases is Humira, though it […]


Newer Treatments for Psoriasis
  by drppanda
Here are some good news for patients of psoriasis.Amplify’d from www.medscape.comPsoriasis Responds Well to Switch From Etanercept to AdalimumabNEW YORK (Reuters Health) Aug 12 - Results of a […]



Other reviews about Adalimumab on web:

Adalimumab (HUMIRA, Abbott) is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds ... Adalimumab - Wikipedia, the free encyclopedia


HUMIRA (adalimumab) is a medication approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) and Crohn's disease (CD). HUMIRA (adalimumab) Medication


Explains the medication adalimumab (Humira), a drug used for reducing the signs and symptoms of rheumatoid arthritis. adalimumab (Humira) - drug class, medical uses, medication side ...


Adalimumab Brand names: Humira® Drug Forms: Adalimumab Solution for injection (below) Adalimumab Injection Español: Adalimumab, Solución para Adalimumab: Information from Answers.com


All about Adalimumab. View complete and up to date Adalimumab information - part of the Drugs.com trusted medication database. Adalimumab Facts and Comparisons at Drugs.com


Physician reviewed adalimumab patient information - includes adalimumab description, dosage and directions. adalimumab medical facts from Drugs.com


Adalimumab. Authoritative facts about the skin from the New Zealand Dermatological Society. Adalimumab. DermNet NZ


Consumer information about the medication ADALIMUMAB - INJECTION (Humira), includes side effects, drug interactions, recommended dosages, and storage information. Read more ... ADALIMUMAB - INJECTION (Humira) side effects, medical uses, and ...


Pronunciation: ay da LIM yoo mab Brand: Humira Humira Pen Humira Pen Crohn's Disease Starter Package What is the most important information I should adalimumab - MSN Health & Fitness - Medications


Learn more about Adalimumab. Find the Web's best health guides, medical reports, news, videos and tools for Adalimumab. Share Adalimumab experiences and get advice from experts. Adalimumab Overview - References, Advice, News, Videos, Coping ...





Featured Reviews

Reviews Piperacillin and Tazobactam Injection

Zosyn Drug Description Zosyn® (piperacillin and tazobactam) Injection To reduce the development of drug-resistant bacteria and maintain the effectiveness of Zosyn (piperacillin and tazobactam) injection and other antibacterial drugs, ...
Read More  |  Review This
Reviews Epinastine HCl Ophthalmic Solution

Elestat Drug Description ELESTAT® (epinastine HCl) Ophthalmic Solution 0.05% Sterile DRUG DESCRIPTION What are the possible side effects of epinastine ophthalmic (Elestat)? Serious side effects are not expected to occur with...
Read More  |  Review This
Reviews Albuterol Sulfate Inhalation Aerosol

Proair HFA Drug Description PROAIR HFA (albuterol sulfate) Inhalation Aerosol DRUG DESCRIPTION What are the possible side effects of albuterol inhalation (Accuneb, ProAir HFA, Proventil, Proventil HFA, Ventolin HFA)? Stop using...
Read More  |  Review This
Reviews Isopto Hyoscine

Isopto Hyoscine Drug Description DRUG DESCRIPTION What are the possible side effects of scopolamine ophthalmic (Isopto Hyoscine)? If you experience any of the following serious side effects, stop using scopolamine ophthalmic...
Read More  |  Review This
Reviews Lamivudine

Epivir Drug Description EPIVIR (lamivudine) Tablets and Oral Solution WARNING: RISK OF LACTIC ACIDOSIS, EXACERBATIONS OF HEPATITIS B IN I , CO-INFECTED PATIENTS UPON DISCONTINUATION OF EPIVIR®, DIFFERENT FORMULATIONS OF EPIVIR. ...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....